Genetic studies promise to provide insight into the molecular mechanisms underlying type 2 diabetes (T2D). Variants associated with T2D are often located in tissue-specific enhancer clusters or super-enhancers. So far, such domains have been defined through clustering of enhancers in linear genome maps rather than in three-dimensional (3D) space. Furthermore, their target genes are often unknown. We have created promoter capture Hi-C maps in human pancreatic islets. This linked diabetesassociated enhancers to their target genes, often located hundreds of kilobases away. It also revealed >1,300 groups of islet enhancers, super-enhancers and active promoters that form 3D hubs, some of which show coordinated glucose-dependent activity. We demonstrate that genetic variation in hubs impacts insulin secretion heritability, and show that hub annotations can be used for polygenic scores that predict T2D risk driven by islet regulatory variants. Human islet 3D chromatin architecture, therefore, provides a framework for interpretation of T2D genome-wide association study (GWAS) signals.
T ype 2 diabetes affects more than 400 million people worldwide 1 , and is a classic example of a polygenic disease in which the genetic susceptibility is largely driven by noncoding variants 2, 3 . T2D susceptibility variants are enriched in active islet enhancers that cluster in linear genome maps-variously defined as super-enhancers, clusters of open regulatory elements (COREs), enhancer clusters or stretch enhancers [4] [5] [6] [7] . Enhancer clusters from other tissues or cell types are similarly enriched in risk variants for
Human pancreatic islet three-dimensional chromatin architecture provides insights into the genetics of type 2 diabetes
Articles NATure GeNeTICS various common diseases 5, [7] [8] [9] [10] [11] . So far, however, genome-wide maps of enhancer clusters have been largely defined with unidimensional epigenomic maps, which do not necessarily reflect the capacity of enhancers to cluster in 3D space, as shown for well-characterized loci such as Hbb (β-globin) and Hoxd 12, 13 . In addition, linear maps do not reveal the target genes of enhancers, which are often separated by hundreds of thousands of base pairs. Therefore, there is a need to obtain accurate representations of enhancer domains, and to connect them to the target genes that underpin disease mechanisms.
Here, we used promoter capture Hi-C (pcHi-C) 14 to generate a genome-scale map of interactions between gene promoters and their regulatory elements in human pancreatic islets. This uncovered ~1,300 hubs of islet enhancers that cluster in 3D space. We show that islet enhancer hubs are connected with key islet gene promoters and exhibit properties of regulatory domains. We use genome/epigenome editing to demonstrate the functional connectivity of hubs and we validate functional interactions between enhancers bearing T2D risk variants and their target genes. Finally, we show that islet hubs not only are enriched for T2D association signals, but also can be used to partition polygenic scores to identify T2D genetic susceptibility driven by pancreatic islet regulatory variation.
Results
The promoter interactome of human islets. To create a genomewide, high-resolution map of long-range interactions between gene promoters and distant regulatory elements in human pancreatic islets, we prepared Hi-C libraries from four human islet samples, and then performed hybridization capture of 31,253 promoter-containing HindIII fragment baits and their ligated DNA fragments. These were then sequenced and processed with the CHiCAGO algorithm to define 175,784 high-confidence interactions (CHiCAGO score > 5) between annotated promoters and distal promoter-interacting DNA fragments 14, 15 (Fig. 1a,b and Supplementary Fig. 1 ). These high-confidence interactions were called with pooled samples, but for 89% of interactions all individual samples showed CHiCAGO scores above the 95% confidence interval of random distance-matched regions ( Supplementary Fig. 1d-g ). We also validated pcHi-C landscapes by 4C-seq analysis in the EndoC-βH1 human β cell line in two selected loci ( Supplementary Fig. 1h,i) .
To define the chromatin landscape of interacting regions, we refined existing human islet epigenome annotations by generating human islet ATAC-seq maps and 30 new chromatin immunoprecipitation (ChIP)-seq datasets (Fig. 1b-d and Supplementary Table 1) . This enabled a subclassification of active enhancers according to Mediator, cohesin and H3K27ac occupancy patterns (Fig. 1b-d and Supplementary Dataset 1). As expected, promoter-interacting genomic regions were enriched in active enhancers, promoters and CTCF-bound regions ( Fig. 1e and Supplementary Fig. 2a-c) . pcHi-C interactions observed in pcHi-C maps from distant cell types were enriched in CTCF-binding sites and active promoters, whereas islet-selective interacting regions were enriched in active enhancers (particularly those with strongest Mediator occupancy, which we term class I enhancers) and were connected with genes showing islet-specific expression ( Supplementary Fig. 2d-f ). This genomescale map of the human pancreatic islet promoter interactome is accessible for visualization along with pcHi-C maps of other human tissues (www.chicp.org) 16 , or as virtual 4C representations of all genes along with islet regulatory annotations (isletregulome.org) 17 .
Identification of target genes for islet enhancers. Long-range chromatin interactions are largely constrained within topologically associating domains (TADs), which typically span hundreds of kilobases (kb) and are often invariant across tissues ( Supplementary  Fig. 3a -e) 18, 19 . TADs, however, define broad genomic intervals that do not necessarily inform on the specific interactions that take place in each tissue between individual cis-regulatory elements and their target genes. Human islet pcHi-C maps identified high-confidence pcHi-C interactions (CHiCAGO score > 5) between gene promoters and 18,031 different islet enhancers (Fig. 2a) . Remarkably, 42.2% of enhancers that showed interactions with gene promoters had high-confidence interactions with more than one gene, thereby illustrating an unexpected complexity of islet enhancer-promoter interactions ( Supplementary Fig. 3f ).
We used pcHi-C maps to further expand the number of enhancers that could be assigned to target genes. We reasoned that interactions between enhancers and their target genes can be missed due to the stringency of detection thresholds, the strong bias of Hi-C methods against proximal interactions or their dependence on specific environmental conditions. To impute additional enhancer-promoter assignments, we considered promoter-associated three-dimensional spaces (PATs). A PAT space was defined as the space containing all pcHi-C interactions that stem from a promoter bait ( Supplementary Fig. 3g,h ). We observed that PATs that had one high-confidence enhancer-promoter interaction were more likely to show other enhancer-promoter interactions, and they exhibited chromatin features that distinguished them from other PATs ( Supplementary Fig. 3i-k) . This prompted us to leverage PAT features to impute plausible target promoter(s) of an additional 18,633 islet enhancers that did not show high-confidence interactions ( Fig. 2a ; see Supplementary Fig. 3l and Methods for a detailed description of the imputation pipeline). Imputed promoterenhancer pairs showed higher CHiCAGO scores than distancematched regions (Kruskall-Wallis P < 10
), suggesting that many imputed assignments represent physical interactions that do not reach our stringent significance thresholds ( Supplementary Fig. 3m ). In total, we used high-confidence interactions and imputations to assign 36,664 human islet active enhancers (80% of all enhancers) to at least one target gene ( Fig. 2a and Supplementary Dataset 2) .
We validated these enhancer-to-gene assignments with complementary approaches. First, we calculated normalized H3K27ac signals in assigned enhancer-promoter pairs across human tissues and human islet samples, and found that assigned pairs had distinctly higher correlation values than enhancers paired with distancematched promoters from the same TAD or an overlapping PAT (Fig. 2b) . Importantly, this was true for both high-confidence and imputed assignments (Fig. 2b) . As expected, islet-selective expression was enriched in enhancer-assigned genes but not in unassigned genes from the same TAD ( Supplementary Fig. 3n ). Furthermore, we determined 1,091 expression quantitative trait loci (eQTL) genes (eGenes) from 183 human islet samples (Supplementary Table 2) , and found that eQTLs were enriched in enhancer-to-gene assignments determined through either high-confident interactions or imputations, compared with distance-matched regions (odds ratio 3.18 and 4.36; P = 3.05 × 10 −9 and 9.01 × 10
, respectively) (Fig. 2c) . We further tested enhancer-promoter assignments in a dynamic perturbation model. We exposed human islets from seven donors to moderately low (4 mM) or high (11 mM) glucose for 72 h, which correspond to quasi-physiological glucose concentrations. This led to glucose-dependent H3K27ac changes in 3,850 enhancers at adjusted P < 0.05, most of which showed increased activity at high glucose ( Supplementary Fig. 3o ). This result, therefore, showed that changes in glucose concentrations elicit quantitative chromatin changes in a large number of human islet enhancers. We next reasoned that glucose-regulated enhancers should tend to cause glucose-regulated expression of their target genes. Indeed, we observed that glucose-induced enhancers were preferentially assigned to genes showing glucose-induced messenger RNA, compared with distance-matched active control genes from the same TAD (odds ratio 2.7 and 2.6, Fisher's P = 4.9 × 10 −16 and 6.4 × 10
, for high-confidence or imputed assignments, respectively) (Fig. 2d) . Likewise, genes assigned to glucose-induced enhancers showed greater glucose induction of promoter H3K27ac than of distancematched promoters in the same TAD (Fig. 2e) . Collectively, these
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Genome editing of T2D-relevant enhancers. A fundamental challenge to translate GWAS data into biological knowledge lies in identifying the target genes of noncoding elements that carry disease-associated regulatory variants. To link noncoding variants to their target genes, we compiled T2D-and fasting glycemia (FG)-associated variants from 109 loci, most of which have been finemapped to a credible set ( Supplementary Fig. 4a and Supplementary Dataset 3). For fine-mapped loci, variants with a high posterior probability (PP > 0.1) of being causal were most enriched in active islet enhancers (Z = 20.9 relative to control regions in the same locus) and promoters (Z = 7.2) (Z < 2 for other accessible chromatin regions) ( Supplementary Fig. 4b ). In 61 loci we identified T2D-and/or FG-associated variants overlapping islet enhancers, and assigned one or more candidate target genes for 53 (87%) of these ( Fig. 3a and Supplementary Table 3 ). Some of these target genes were expected, based on their linear proximity to the variants (for example, ADCY5, TCF7L2, ZFAND3, PROX1, FOXA2), but for 75% of loci we identified more distant candidate genes. Examples of unexpected distal target genes, sometimes in addition to previously nominated proximal genes, include SOX4 (in the CDKAL1 locus),
(ZFAND3) and PHF21A (CRY2) ( Fig. 3a and Supplementary  Table 3 ; see isletregulome.org or www.chicp.org). Selected unexpected targets, including ABCB9 and STARD10, were additionally supported by concordant eQTLs ( Supplementary Fig. 4c,d) .
We used genome editing to validate target genes of ten enhancers bearing T2D-or FG-associated variants from eight loci ( Fig. 3b and Supplementary Table 4 ). We performed these experiments in EndoC-βH3 cells, a glucose-responsive human β cell line 20 .
In the CDC123/CAMK1D locus, only one SNP from a small set of fine-mapped T2D-associated variants is located in an islet enhancer (Fig. 3c, Supplementary Fig. 5a ,b and Supplementary Table 3 ). This variant was previously proposed to be a regulatory variant on the basis of plasmid reporter studies 21 , allele-specific chromatin accessibility 22 and as an eQTL for CAMK1D 23, 24 (Supplementary  Table 2 ). The enhancer showed moderate-confidence interactions (CHiCAGO = 4.42) with CAMK1D, but, more surprisingly, showed high-confidence pcHi-C interactions with a more distant gene, OPTN ( Fig. 3c and Supplementary Fig. 5a ). Accordingly, deletion of this enhancer (but not an adjacent region), or silencing with KRAB-dCas9, led to selectively decreased expression of both OPTN and CAMK1D, whereas targeted activation of the enhancer stimulated their expression ( Fig. 3d and Supplementary Fig. 5c,d ). These results, therefore, confirm functional relationships predicted by pcHi-C maps. Although the role of OPTN and CAMK1D as mediators of this T2D-associated genetic signal remains to be defined, the 
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findings highlight an example of a diabetes-relevant enhancer with multiple target genes.
We also examined rs7903146, a plausible causal SNP in the TCF7L2 locus. This is the strongest known genetic signal for T2D, and it is known to influence islet cell traits in non-diabetic individuals 2, 25, 26 . SNP rs7903146 lies in a class I enhancer with unusually high Mediator occupancy (Supplementary Fig. 6a ). The SNP alters allelespecific accessibility and episomal enhancer activity 6 , and has been associated with differences in TCF7L2 mRNA 27 . However, deletion of this enhancer in human colon cancer cells affects ACSL5 rather than TCF7L2 (ref. 28 ), thereby questioning the true target gene(s) of this enhancer in islet cells. We found that the rs7903146-bearing enhancer has imputed and moderate-confidence pcHi-C interactions with TCF7L2, but no evidence of proximity with any other gene in human islets (Supplementary Fig. 6a ). Consistently, targeted deletion, functional inhibition or stimulation of the enhancer caused selective changes in TCF7L2 mRNA ( Supplementary Fig. 6b,c) . Therefore, the enhancer that harbors rs7903146 regulates TCF7L2 in human β cells. Regardless of the possible metabolic role of this locus in other cell types 29 , this finding indicates that TCF7L2 is a likely mediator of the genetic association between rs7903146 and islet-related traits.
For all eight tested loci, at least one of the genes assigned by pcHi-C to an enhancer showed gene expression changes, and four showed changes in expression of more than one gene (Fig. 3b , Supplementary Table 4 PAT features allowed imputing the assignment of promoters to another 40% of all active enhancers (see Supplementary Fig. 3l ,m for further details and evidence that imputed assignments are enriched in subthreshold interactions). b, Functional correlation of enhancer-gene pairs assigned through high-confidence interactions (n = 18,637 pairs) or imputations (n = 28,695 pairs). Spearman's rho values for normalized H3K27ac signal in enhancer-promoter pairs across 14 human islet samples and 51 Roadmap Epigenomics tissues. Control enhancer-gene pairs were enhancers that overlapped a PAT in linear maps but were not assigned to the PAT promoter (n = 9,770 pairs), or other unassigned gene-enhancer pairs from the same TAD (n = 20,186 pairs). c, Concordance of enhancer eQTL-eGene pairs and enhancers-gene pairs assigned through high-confidence interactions (n = 351 pairs) or imputations (n = 293 pairs) relative to distance-matched control regions (n = 579 and 593 pairs, respectively), shown as a fold change. P values were derived from one-sided Fisher's exact test. d, Genes assigned to glucose-induced enhancers showed concordant glucose-induced expression. Glucose-induced enhancers showed enriched high-confidence (n = 439) or imputed (n = 640) assignments to glucose-induced genes, compared with distance-matched genes from the same TAD (top). Glucose-induced enhancers showed no enrichment for assignments to genes that were inhibited by high glucose concentrations (n = 196 interacting and n = 218 imputed pairs) (bottom). OR, odds ratio. P values were calculated with chi-square tests. e, Genes assigned to glucose-induced enhancers through high-confidence interactions (n = 275) or imputations (n = 321 pairs) were enriched for glucose-induced promoter H3K27ac, compared with control genes from the same TAD. Box plots represent interquartile ranges (IQRs), notches are 95% confidence intervals of median, P values are from Wilcoxon's two-sided signed ranked tests. See also Supplementary Dataset 2.
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functionally validated imputed target genes, such as VEGFA, as well as MDGA1 and ZFAND3 ( Supplementary Fig. 7 ). These functional studies, therefore, underscore the complexity of enhancer-promoter interactions, with long-range interactions that cannot be predicted from linear genome maps, interactions that are not functionally essential and frequent target gene multiplicity. Importantly, the results validate the use of human pcHi-C maps to connect regulatory elements that harbor T2D-associated Table 3 ). b, Summary of T2D-associated enhancer perturbations presented in this study (see also Supplementary Table 4 ). NT, not tested. c, Islet pcHi-C analysis defines gene targets of an enhancer bearing T2D-associated variants near CDC123/CAMK1D. The only T2D risk credible set variant that maps to an islet enhancer in the locus (rs11257655, zoomed inset) is assigned to CAMK1D and OPTN (dashed horizontal lines). Islet pcHi-C virtual 4C representations from pooled samples show interactions stemming from both CAMK1D and OPTN promoters towards rs11257655 with CHiCAGO > 3, but not from CDC123. d, CAMK1D and OPTN mRNA are regulated by the rs11257655-containing enhancer. We deleted the rs11257655-containing enhancer and a nearby control region with a T2D-associated variant (rs33932777) that lacked active chromatin marks in human islets. Cas9 only: n = 6 (two independent experiments with triplicates). Deletions: n = 8 (two guide RNA (gRNA) pairs in two independent experiments with biological duplicates). Bars are mean ± s.e.m., normalized by TBP and expressed relative to mean levels of the Cas9 only controls. Statistical significance: two-tailed Student's t-test.
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variants with the genes that can mediate disease susceptibility mechanisms.
Islet-specific transcription is linked to enhancer hubs.
Earlier studies demonstrated that risk variants for common diseases such as T2D are enriched in clusters of enhancers that regulate key cell identity genes [4] [5] [6] [7] . However, spatial clustering of enhancers is not necessarily apparent from linear genome maps. To identify 3D enhancer clusters, we again considered promoter-associated 3D spaces, or PATs, and empirically defined enhancer-rich PATs as those containing three or more class I enhancers (enhancers with high H3K27ac and Mediator occupancy, Fig. 1c ). This definition of enhancer-rich PATs was supported by a multivariate analysis of genomic and epigenomic PAT features that were most predictive of islet-specific gene expression (Supplementary Fig. 8a and Methods). In total, we identified 2,623 enhancer-rich PATs ( Supplementary  Fig. 8b ). As noted above, many active enhancers (~40%) had interactions with one or more promoters ( Supplementary Fig. 3f ). Thus, separate enhancer-rich PATs were often connected. We therefore merged enhancer-rich PATs with other PATs connected through enhancer-mediated high-confidence interactions, yielding 1,318 islet enhancer hubs ( Fig. 4a and Supplementary Fig. 8c ). Compared to alternative enhancer hub definitions, this definition maximized the enrichment of islet cell functional annotations and the number of mapped hubs ( Supplementary Fig. 9 ). The 1,318 islet enhancer hubs are, in essence, 3D chromatin domains that contain a median of 18 enhancers, two active promoters and two shared enhancer interactions ( Supplementary Fig. 8d ). They are often Table 6 and Supplementary Dataset 5.
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NATure GeNeTICS tissue-selective interaction domains, because hub promoters had a 2.8-fold higher fraction of islet-selective interactions than did nonhub promoters (Wilcoxon's P = 2.8 × 10
) (Supplementary Fig.  8e ; examples in Figs. 1b and 5a and Supplementary Figs. 1h,i and  10a) . Furthermore, the genes that form part of enhancer hubs were enriched in islet-selective transcripts, and in functional annotations that are central to islet cell identity, differentiation and diabetes ( Hubs exhibit domain-level chromatin changes. Consistent with the high internal connectivity of hubs, gene pairs from the same hub showed increased RNA expression correlation values across tissues and islet samples, as compared to control active gene pairs in the same TAD as the hubs (P = 6.3 × 10 −8 ) (Fig. 4d) . Moreover, hub enhancers showed higher H3K27ac correlations with their target promoters than when they were paired with non-hub promoters from the same TAD (P = 2.2 × 10 −16 ) (Fig. 4e) . These findings are consistent with enhancer interaction hubs as functional regulatory domains.
To further explore the behavior of hubs as functional domains, we again examined islets exposed to moderately low versus high glucose concentrations. Glucose-induced enhancers and mRNAs were highly enriched in hubs, compared with their non-hub counterparts (Fisher's P = 1. 
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promoters that showed glucose-induced H3K27ac, 94 were contained in hubs, and 65% of these showed glucose-induced mRNA (Supplementary Tables 6 and 7) . We predicted that if hubs are functional regulatory domains, hub enhancers connected to glucoseinduced genes should tend to show coordinated glucose-dependent changes. Our analysis showed that hub enhancers assigned to glucose-induced promoters showed a widespread parallel increase in H3K27ac (Fig. 4f-h and Supplementary Table 8 ). Thus, varying glucose concentrations elicit chromatin changes in human islets at the level of broad regulatory domains. Taken together, our findings indicate that enhancer hubs have properties of functional units.
Enhancer hubs contain super-enhancers and enhancer clusters.
We compared islet enhancer hubs with previously defined islet enhancer domains, such as linear enhancer clusters and superenhancers ( Supplementary Fig. 8f ). This showed that hubs have at least some spatial overlap with 70% of enhancer clusters 7 , and with 87% of super-enhancers defined with a standard algorithm 4 ( Supplementary Fig. 8g-i) . Hubs, however, differ in that they can be connected with their target genes. Furthermore, enhancer hubs capture spatial clusters of Mediator-bound (class I) enhancers that do not cluster in the linear genome and therefore do not fulfill definitions of super-enhancers and enhancer clusters ( Supplementary  Fig. 8j-l) 4, 7 . In fact, many hubs contained several interconnected enhancer clusters or super-enhancers ( Supplementary Fig. 8m-o) . This is illustrated by the ISL1 locus, which has several enhancer clusters and super-enhancers distributed across an entire TAD, whereas pcHi-C points to a single hub that connects dozens of enhancers with ISL1 and long noncoding RNA HI-LNC57 (Fig. 5a) .
Thus, enhancer hubs are 3D domains that often include one or more enhancer clusters or super-enhancers and their target gene(s).
Tissue-specific architecture of the ISL1 enhancer hub. To gain insight into the 3D conformation of enhancer hubs, we built 3D models of hubs using islet pcHi-C interaction data (Fig. 5a) . We focused on the ISL1 locus because it contains a single hub within a TAD-like domain, with few other annotated genes. We used islet pcHi-C data to build interaction matrices at 5-kb resolution, and transformed the frequency of interactions between genomic segments into spatial restraints 30, 31 . We then used molecular dynamic optimization to generate an ensemble of 500 models that best satisfied the imposed restraints. This showed colocalization of islet enhancers and target genes in a constrained space of the TAD, whereas models built from B lymphocyte pcHi-C libraries showed decreased aggregation of these regions (Fig. 5b,c, Supplementary  Fig. 10b ,c and Supplementary Videos 1 and 2 ). Quantitative analysis of ISL1 and six other T2D-relevant hubs showed analogous tissue-specific aggregation of hub enhancers and promoters ( Supplementary Figs. 10d-I and 13f-h ). These models, which capture the average topology in a population of cells, serve to highlight that whereas TADs are defined as single intervals in linear genome maps, hubs are formed by multiple interspersed regions that occupy a shared 3D subspace within a TAD.
Epigenome editing of T2D-associated islet hubs. We used enhancer perturbations to test the functional connectivity of selected enhancer hubs. In the ZBED3 locus, we targeted a class I enhancer that contains a variant with highest posterior probability Fig. 10 ). The variant with highest posterior probability in this locus (rs7732130) maps to a class I islet enhancer (yellow line, and zoomed inset) that shows interactions with PDE8B (CHiCAGO > 5) and ZBED3, ZBED3-AS1, SNORA47 and S100Z (CHiCAGO > 3, see also Supplementary Fig. 11 ). WDR41 is assigned to rs7732130 by imputation. Dashed horizontal lines show all targets assigned through imputation or high-confidence interactions. b, Analysis of hub and non-hub transcripts after CRISPR activation or inhibition of the transcriptional start site of ZBED3 or the rs7732130 enhancer in EndoC-βH3 cells. Data are presented as mean ± s.e.m. of all gRNAs combined per target region (enhancer CRISPRa: three gRNAs, CRISPRi: four gRNAs, all n = 3 independent experiments). Statistical significance: two-tailed Student's t-test.
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for causality in T2D fine-mapping studies (PP = 0.461) (Fig. 6a,  Supplementary Fig. 11a and Supplementary Table 4 ). Targeted epigenomic activation or inhibition of this single enhancer led to significant changes in the expression of five of the six genes connected with this hub, but not of non-hub genes from the same TAD (Fig.  6b) . In three other hubs we perturbed single enhancers containing candidate T2D susceptibility causal variants, which led to expression changes in CRY2 and PHF21A ( Supplementary Fig. 11b,c) , VPS13C, C2CD4A and C2CD4B (Supplementary Fig. 12 ) and GLIS3 ( Supplementary Fig. 13 ). These findings highlight a remarkable functional connectivity of enhancer hubs.
Islet hub variants impact insulin secretion. Previous evidence that T2D susceptibility variants are enriched in islet enhancer clusters [5] [6] [7] 24, 32 prompted us to examine the enrichment of diabetes-associated variants in our newly defined annotations. T2D/ FG-associated SNPs were enriched in islet pcHi-C interaction regions (Fig. 7a) and in islet enhancer hub class I enhancers, rather than in other active enhancers (Fig. 7b, Supplementary Figs. 9 and 14a-f and Supplementary Table 9 ). This indicates that hub class I enhancer variants are important for T2D susceptibility.
A major portion of the heritability of common diseases is driven by many variants that, individually, have not achieved genome-wide significance, yet exert a large aggregate effect [33] [34] [35] . Consistent with this notion, common variants that have so far not shown genomewide significance for T2D association, but are located in pcHi-C interacting regions or hub class I enhancers, showed more significant association P values than expected distributions (Fig. 7c,d ). This observation prompted us to quantify the overall contribution of common variants in islet hubs to the heritability of T2D. We used stratified linkage disequilibrium (LD) score regression 36 , and found that hub class I enhancers showed the most significantly increased per-SNP T2D heritability coefficient (q = 1.64 × 10 −2 ) compared with various islet and non-islet genomic annotations (Fig. 7e,  Supplementary Fig. 15a and Supplementary Table 10) .
Although islet dysfunction is central to the pathophysiology of T2D, other tissues (liver, adipose, muscle, brain, among others) are also critically important 37 . Genetic variation in islet hub enhancers should, therefore, predominantly impact on the heritability of pancreatic islet function. Indeed, islet hub variants showed higher heritability enrichment estimates for islet cell traits than for T2D (Fig. 7e, Supplementary Fig. 15a-f and Supplementary Table 10) . Consequently, common variation in hub class I enhancers (0.26% of genomic SNPs) explained 9.9% of observed genetic heritability for T2D, 21.9% for acute insulin secretory response in intravenous glucose tolerance tests 26 , 17.2% for HOMA-B models of β-cell function and 31.2% for an insulinogenic index on the basis of oral glucose tolerance tests (OGTT) 38 (Supplementary Table 10 ). In sharp contrast, islet hub variants showed no enrichment for HOMA-IR, an estimate of insulin resistance (Supplementary Fig. 15e ). Of note is that significant heritability enrichments were generally also observed for enhancer clusters, stretch enhancers or super-enhancer annotations, yet estimates were consistently larger for hub enhancers ( Fig. 7e and Supplementary Fig. 15a-d) . These results indicate that enhancer hubs define genomic spaces that play a prominent role in the heritability of T2D and insulin secretion.
Hub variants provide tissue-specific risk scores. Recent studies suggest that polygenic risk scores (PRS) that integrate effects of a very large number of variants, including many that lack genomewide significant association, can identify individuals with extreme levels of risk for polygenic diseases, including T2D 33, 35, [39] [40] [41] . We assessed whether islet hub variants could be harnessed to more specifically identify individuals in whom variation in islet function plays a preponderant role in T2D susceptibility.
We first created a PRS model using all common variants from a recent body mass index (BMI)-adjusted T2D GWAS meta-analysis 42 , and examined the ability of this genome-wide PRS to predict T2D in the UK Biobank population cohort 43, 44 . This showed that 2.5% of the UK Biobank individuals with the highest PRS had a 7.11-fold higher frequency of T2D than those with the lowest 2.5% (Fig. 7f) .
Next, we created PRS models that contained DNA variants from either: (1) islet hub enhancers and promoters (1.6% of the genome), (2) all other islet open chromatin regions (5.0% of the genome) or (3) the rest of the genome. Despite the fact that islet hub regions encompass <2% of the genome, the T2D risk ratio-defined as the T2D frequency in the top versus bottom risk bins-was 4.02-fold, which was comparable to that observed with variants from the rest of the genome (risk ratio 3.96), and larger than that of other open chromatin regions (risk ratio 3.01) (Fig. 7f and Supplementary Fig.  15g,h ). Thus, islet hub variants possess a capacity to predict T2D risk that plausibly reflects their observed impact on the heritability of islet function (Fig. 7e) .
Although, as expected, the genome-wide PRS model shows higher risk ratios than islet hub PRS models (Fig. 7e) , the latter could potentially define qualitatively distinct T2D risk profiles. Monogenic defects in islet transcription factors typically cause early-onset diabetes in lean individuals, suggesting that islet cisregulatory variants could also predominantly impact T2D risk at an earlier age and lower BMI. We thus compared the effect of hub PRS across BMI and age of onset of diabetes, and considered how it deviated from PRS calculated from genomic regions of similar size and distribution as hubs (100 iterations of 1,000 pseudo-enhancer hubs redistributed across TADs). For hub PRS, this T2D risk ratio showed greatest deviations from pseudo-hub PRS in individuals with BMI < 30 (hub risk ratio = 6.25, Z = 5.68) and T2D diagnosed before 50 years (hub risk ratio = 6.67, Z = 5.27), but then sharply Table 9 ) and breast cancer (n = 3,048 variants) in high-confidence interacting fragments in islets. Box plots show 500 permutations of matched random haplotype blocks. Red dots indicate significant enrichments (Bonferroni-adjusted P < 0.01). NS, not significant. b, T2D and FG GWAS significant variants are selectively enriched in hub class I islet enhancers. Box plots show median and IQR. c, Genomic inflation of T2D association P values for non-GWAS significant variants (P > 5 × 10 7 and are shown with s.e.m. f, T2D frequency across 40 bins, each representing 2.5% of individuals in the UK Biobank test dataset (226,777 controls; 6,127 T2D cases) with increasing PRS, calculated with hub (pink dots) or genome-wide variants (light green). g, Odds ratios (OR) for T2D calculated for 2.5% individuals with highest PRS versus all other individuals, using islet hub (pink) or genome-wide models (green), stratified by BMI and T2D age of onset. Box plots show ORs for PRS from 100 permutations of pseudo-hubs (IQRs). Z-scores are standard deviations of pseudo-hub averages. See also Supplementary Fig. 15 and Supplementary Table 17 .
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NATure GeNeTICS declined with increasing BMI and age of onset of T2D (BMI ≥ 35, hub risk ratio = 2.67, Z = 2.98; T2D onset ≥60 years, hub risk ratio = 3.01, Z = 2.94) (Supplementary Fig. 15h ). This contrasted from PRS models built with the rest of the genome, which showed greatest deviations from pseudo-hubs in individuals with BMI > 35 and T2D diagnosed after 65 Fig. 15h ). We further stratified UK Biobank individuals by both BMI and age of onset of diabetes, and found that individuals with 2.5% top hub risk scores had an odds ratio of 2.71 for T2D diagnosed at <60 years of age and BMI < 35 (Fig. 7g ). This odds ratio was a major deviation from that observed with pseudo-hub PRS (Z = 8.50), and was equivalent to the T2D risk of the highest genome-wide PRS ( Fig. 7g ; see Supplementary  Fig. 15i for other control regions) . At the other extreme of the phenotypic spectrum (BMI ≥ 35 and age of onset ≥ 60), individuals with the highest islet hub PRS showed a lower odds ratio, which did not differ from pseudo-hub genomic regions (odds ratio = 1.52, Z = 0.37) (Fig. 7g) . Taken together, these results indicate that islet enhancer hub variants, which impact islet gene regulation and insulin secretion, can provide distinct T2D risk scores.
Discussion
We have created human islet 3D genome maps that link human pancreatic islet enhancers to gene promoters. We validated them with experimental perturbation models and eQTLs, and showed how they can identify the target genes of diabetes-relevant regulatory elements. This resource can therefore assist efforts to understand the molecular mechanisms that influence T2D susceptibility. Our study has systematically mapped >1,300 enhancer hubs in human islets. These enhancer domains align with earlier observations derived from lower resolution Hi-C maps, which showed broad genomic regions that exhibit unusually high interaction frequencies 45 , with numerous well-characterized chromatin hubs 12, 13 , and with evolutionarily conserved noncoding sequence blocks 46, 47 . We show that enhancer hubs exhibit features of regulatory domains that control genes important for islet cell function, differentiation and diabetes. They also contain DNA variants that have a major impact on the heritability of insulin secretion. Hub elements, therefore, define a genomic space that has direct relevance to islet function and human diabetes. Islet enhancer hubs should thus provide a useful gene-centric framework for genetic studies that aim to discover regulatory variants underlying T2D and monogenic diabetes.
Our work is relevant to the dissection of the polygenic underpinnings of T2D. Recently, genome-wide polygenic risk scores have shown promise for the prediction of common diseases 35 . Because T2D pathophysiology is heterogeneous and multiorganic 37, 48, 49 , it is reasonable to presume that partitioned polygenic risk scores could also provide risk estimates that distinguish mechanisms of susceptibility across individuals. Polygenic scores based on islet hub variants could thus be leveraged to quantify patient-specific genetic risk acting through islet gene regulation and insulin secretion.
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Methods
Human islets. Human pancreatic islets from organ donors without a history of glucose intolerance were purified using established isolation procedures [50] [51] [52] [53] , shipped in culture medium and re-cultured at 37 °C in a humidified chamber with 5% CO 2 in glucose-free RPMI 1640 supplemented with 10% fetal calf serum, 100 U ml −1 penicillin, 100 U ml −1 streptomycin and 11 mM glucose for 3 d before analysis. RNA was extracted from flash-frozen islet pellets using TRIzol Reagent (ThermoFisher Scientific). For glucose regulation studies, islets were cultured in identical time and medium, except that glucose-free RPMI 1640 medium was supplemented with glucose to achieve final concentrations of either 4 or 11 mM glucose. Donor and sample characteristics are provided in Supplementary Table 11 .
Compliance with ethical regulations for human research studies is described in Supplementary Note 1. pcHi-C. From four islet donors, 30-60 million human islet cells per donor were cultured as described above for 3 d before fixation in 2% paraformaldehyde (Agar Scientific) at room temperature for 10 min with mixing, quenched in 125 mM glycine for 5 min at room temperature and 15 min in ice and washed twice in PBS. Dry pellets were flash-frozen and stored at −80 °C.
Hi-C libraries were prepared with in-nucleus ligation and processed to capture 22,076 HindIII fragments containing 31,253 annotated promoters for 18,202 protein-coding and 10,929 non-protein-coding genes (Ensembl v.75), using SureSelect target enrichment (Agilent Technologies), as described previously 14, 54 . After library enrichment, a post-capture PCR amplification step was carried out with four PCR amplification cycles.
Twelve sequencing replicates from four human islet donor libraries were processed using a reported pipeline that maps di-tags against the human genome (GRCh37), filters out experimental artifacts, such as re-ligations, and removes PCR duplicates 55 . Reads from replicates from each donor were then pooled. Alignment statistics are shown in Supplementary Tables 12 and 13 .
Interaction confidence scores were computed with CHiCAGO 14, 15 . Highconfidence interactions were defined as CHiCAGO scores >5, as described 14 . pcHi-C datasets from unrelated tissues 14 were processed identically. CHiCAGO analysis is generally performed with pooled libraries as this increases sensitivity and mitigates subsampling in individual libraries 14, 15 . We assessed reproducibility across individual samples, and observed that high-confidence interaction calls showed (1) high CHiCAGO scores in individual samples, with limited overlap with distance-matched regions ( Supplementary Fig. 1d) , (2) Supplementary Fig. 1e ) and (3) consistent above-background scores in individual samples ( Supplementary  Figs. 1f,g and 5a) .
ChIP-seq and ATAC-seq. ChIP and ATAC were performed as previously described 7, 56 , with modifications (Supplementary Note 2). Adaptor trimming of ChIP-seq reads was performed with cutadapt v.1.9.1 (options: -m 20) 57 . For ATACseq, low quality bases and adaptor trimming were processed using TrimGalore v.0.4.1 (options: --quality 15 --nextera). Trimmed reads were aligned to hg19 using bowtie2 v.2.1.0 (options: --no-unal) allowing no mismatches 58 , retaining uniquely mapped reads (MAPQ ≥ 30) using SAMtools v.1.2 (ref. 59 ), removing duplicate reads (picard v.2.6.0) 60 , blacklisted regions 61 and, for ATAC-seq, mitochondrial reads. Data quality was assessed with SPP.R script from phantompeaktools 62 . ChIPseq and ATAC-seq information is shown in Supplementary Table 1. For histone modifications, broad enriched regions were called with MACS2 (ref.
63
) using --g hs --extsize = 300 --keep-dup all --nomodel --broad, and narrow regions were called without using --broad flag. For transcription factors and cofactors, narrow regions were called using --g hs --extsize = 300 --keep-dup all. For ATAC-seq, we used --shift 100 --extsize = 200 --keep-dup all --nomodel.
To obtain a robust set of ChIP-seq peaks, we called peaks in individual human islet samples with relaxed stringency (P < 0.01), and in pooled samples using a stringent threshold (false discovery rate (FDR) q < 0.05 for Mediator and cohesin; and q < 0.01 for histone modification marks). We then identified peaks present in at least three individual samples, or at least two samples if only three replicates were processed, as well as in the pooled set. For accessible chromatin sites, we called peaks at P < 0.01 in 13 individual samples, and FDR q < 0.05 from pooled samples. We then defined consistent peaks present in at least three samples as well as in the pooled set. Consistent ATAC peaks that showed multiple subpeaks in >3 islet samples were manually split, leading to n = 241,481 ATAC peaks. A final set of accessible chromatin regions (n = 249,582) was defined by adding regions lacking ATAC-seq peaks that showed either Mediator or CTCF binding (n = 1,319, n = 9,596 respectively) or were bound by at least two islet transcription factors (n = 1,514) 7 . bigWig files were generated using bamCoverage from deepTools (-e = 300 --normalizeTo1x2451960000).
Classification of human islet-accessible chromatin. We classified 249,582 consistent islet open chromatin regions using k-medians clustering of ChIP-seq signal distributions of H3K27ac, H3K4me1, H3K4me3, Mediator, cohesin and CTCF, using islet samples with the greatest signal to noise for these marks. Briefly, −log 10 (P value) signal was calculated for each mark using 100 base pair bins across a 6-kb window centered on consistent open chromatin regions. K-median clustering (flexClust 64 ) was used to classify open chromatin regions into 14 clusters, which were manually merged into eight clusters based on the chromatin mark enrichment patterns. Each open chromatin class was ranked by CTCF binding to highlight a subset of CTCF-bound enhancers. Post-hoc analysis showed that human islet transcription start sites defined by cap-analysis of gene expression (CAGE) were markedly enriched in regions classified as active promoters and, to a lesser extent, in class I enhancers (Fig. 1c) . See Supplementary Dataset 1 for genomic locations.
PATs and enhancer-promoter assignments. We defined 16,030 promoterassociated three-dimensional spaces (PATs) as the linear space covered by all interactions originating from a pcHi-C bait, within the same islet TAD-like compartment (Supplementary Note 3) .
We used PAT features to assign enhancers to promoters, following a stepwise approach such that each step was performed on unassigned enhancers from previous steps. We assigned enhancers to baits with at least one active islet promoter according to our regulome annotations (Supplementary Dataset 1) or ChromHMM analyses (Supplementary Note 6), and report target genes with average human islet RNA expression >1.5 transcripts per million (TPM) (Supplementary Dataset 2) , based on the following criteria:
(1) Presence of high-confidence interactions (CHiCAGO > 5) to one or more baits, including those that cross TAD boundaries (also referred to as assignment by interaction). (2) For enhancers with no high-confidence interactions, we defined PAT(s) in which they were contained. We did not assign enhancers to all overlapping PATs because only some active genes are regulated by enhancers, and instead only imputed orphan enhancers to PAT(s) anchored by an active promoter that already showed high-confidence interactions with other islet enhancers. (3) For remaining enhancers located <10 kb away from a bait containing active promoter(s), we assumed that (1) this linear distance is more likely to provide functional enhancer-promoter communication than for promoters located more distally that do not show high-confidence interactions, and (2) random collisions are too frequent to detect high-confidence interactions above background noise, and thus we imputed these enhancer-promoter assignments. (4) For the remaining enhancers that were exclusively contained within a single PAT with an active promoter, we imputed the assignment to expressed genes in that PAT bait. We refer to assignment criteria 2-4 as imputations here.
Enhancer-promoter assignments can be found in Supplementary Dataset 2 and were validated by analysis of (1) CHiCAGO scores in imputations, (2) increased enhancer-promoter correlations, (3) islet-specificity of assigned genes, (4) concordance with eQTLs and (5) coordinated changes after exposure to varying glucose concentrations (Supplementary Note 7).
Candidate target genes of T2D/FG-associated variants. We integrated lists of T2D/FG-associated variants (Supplementary Note 8) with enhancer-promoter assignments to identify candidate target genes. We associated 555 enhancer variants from 51 loci to islet-expressed genes using high-confidence interactions and imputations. Supplementary Table 3 provides a more extensive list of 830 T2D/FG-associated variants overlapping an active enhancer or promoter, with information on connections to candidate target genes through (1) highconfidence interactions (CHiCAGO > 5), (2) moderate-confidence interactions (CHiCAGO = 2.5-5), (3) imputations, (4) indirect connections through a common hub and (5) location of actively expressed gene within 10 kb. This category also included actively transcribed genes from associated variant-containing promoters that overlap pcHi-C baits. Supplementary Table 3 additionally lists T2D/ FG variants overlapping a promoter-interacting region that do not overlap an annotated regulatory element.
Cell-based genome and epigenome editing. Experimental validation of T2D-relevant enhancer-promoter assignments in EndoC-βH3 cells 20 is described in Supplementary Note 10 and Nature Protocol Exchange (I.C. and A. Beucher, https://protocolexchange.researchsquare.com/article/nprot-7395).
Classification of PATs based on enhancer content. We defined enhancer-rich PATs as those with three or more class I enhancers (Supplementary Fig. 8b ). This was supported by logistic regression analysis (Supplementary Note 11) showing that the number of class I enhancers assigned to a PAT was independently predictive of islet-selective expression of PAT genes. This effect was optimized with PATs with ≥3 assigned class I enhancers (Supplementary Fig. 9 ).
Enhancer hubs. Enhancer-rich PATs were frequently interconnected through one or more shared enhancers (42.4% of all active enhancers had high-confidence interactions with >1 bait). We thus merged enhancer-rich PATs with other PATs that were connected by one or more common enhancers through high-confidence interactions (CHiCAGO > 5). For 99.5% of hubs, all hub components were restricted to one chromosome. Alternative definitions of hubs were created to test how, (1) the number of enhancers in enhancer-rich PATs, (2) the inclusion of enhancer-gene imputed assignments and (3) criteria to merge PATs, influence definitions of enhancer hubs (Supplementary Fig. 9 ).
. The analysis of correlated hub promoter and enhancer activity, and islet selectivity of enhancer interactions, is described in Supplementary Note 12.
3D modeling of hubs. 3D modeling and analysis of enhancer hubs were partly based on previously described methods 66, 67 , and are described in Supplementary Note 13.
T2D/FG variant enrichments in regulatory annotations. Variant set enrichment 68 was used to compute the enrichment of T2D-and FG-associated variants in regulatory annotations, using lead SNPs from 109 loci (Supplementary Table 9) , and is described in Supplementary Note 14.
GWAS meta-analysis of insulin secretion. A total of 7,807 individuals from four population studies were included in these analyses: the Inter99 study (ClinicalTrials ID no.: NCT00289237) (n = 5,305) 38 , the Health2008 cohort (n = 605) 69 , the 1936 Birth Cohort (n = 709) 70 and the ADDITION-Pro cohort (n = 1,188) 71 . All study participants gave informed consent and studies were approved by the appropriate ethical committees in accordance with the scientific principles of the Helsinki Declaration II.
In all cohorts, glucose-stimulated insulin secretion was evaluated by measurement of plasma glucose and serum insulin at 0, 30 and 120 min during a 75-g OGTT. We calculated insulinogenic index = (s-insulin at 30 min [pmol l ). Individuals with known diabetes were excluded.
Two sample sets (Inter99 and Health2008) were genotyped by Illumina OmniExpress array and others by Illumina CoreExome array. Genotypes were called by the Illumina GenCall algorithm. Genotype data were filtered for variants with call rate <98% and Hardy-Weinberg equilibrium P < 10
. Samples were excluded if they were ethnic outliers, had mismatch between genetic and phenotypic sex or had a call rate <95%.
Genotype data were imputed to the Haplotype Reference Consortium reference panel v.1.1 (ref. 72 ) at the Michigan Imputation Server using Minimac3 after phasing genotypes into haplotypes with Eagle2 (ref. 73 ). Post-imputation SNP filtering included exclusion of variants with minor allele frequency (MAF) < 0.01 or info score < 0.70. In each cohort, association analysis was performed by applying a linear regression model including age and sex as covariates via SNPTEST 74 . The phenotype was rank-normalized within each cohort before analysis. A fixed-effects meta-analysis implemented in the R package meta 75 was finally performed.
Heritability estimates.
See also Supplementary Notes 16 and 17. To estimate the polygenic contribution of different genomic annotations to GWAS-based heritability of T2D and related traits, we applied the stratified LD Score regression method 36, 76 . This method leverages the relationship between LD structure and association test statistics to estimate the average per-SNP contribution to heritability (τ c coefficient) of functional genomic categories. We used a panel of 53 baseline genomic annotations 36, 76 , and interrogated a broad range of islet regulatory annotations, including enhancer hubs, as well as control annotation sets, such as central nervous system functional annotations, random non-open chromatin regions and pseudo-enhancer hubs. We provide the per-SNP heritability τ c coefficient for each regulatory annotation. To facilitate comparisons across traits and annotations, we normalized the τ c estimates by dividing them by the LD Score heritability for each phenotype, and multiplied by 10 7 . To correct for multiple testing, we generated τ c q values (FDR-adjusted P values calculated from the Z-scores of the τ c coefficients) with the qvalue R package over 17 functional categories and six traits. The FDR significance threshold was set at 0.05.
PRS.
See also Supplementary Note 18. We created PRS based on T2D GWAS summary statistics from 70kfort2d 42 (base dataset). UK Biobank individuals 43 were used as the target datasets, which comprised training and testing datasets.
To select markers for PRS we first considered all genetic markers that were used as input for phasing and genotype imputation by UK Biobank, and filtered for variants with MAF ≥ 5% and imputation quality score >0.8. We then reconciled the base and target datasets by looking at the variant overlap between summary statistics and the imputed UK Biobank data, discarding variants showing allele inconsistency between both datasets. We also removed those located in the major histocompatibility complex region, resulting in a final collection of 5,352,737 variants.
We excluded UK Biobank individuals with: (1) excess of relatives (showing >10 putative third-degree relatives, as provided by UK Biobank), (2) greater than thirddegree of relatedness (from each pair of related individuals we excluded the subject with the highest missing rate for a set of high-quality markers, as provided by UK Biobank), (3) no gender information, (4) International Classification of Diseases (ICD-10) codes E10 (insulin-dependent diabetes mellitus), E13 (other specified diabetes mellitus) and E14 (unspecified diabetes mellitus), (5) no BMI information. T2D cases were defined by the E11 ICD-10 code.
The sample size of UK Biobank qualifying individuals was 377,981 controls and 15,764 cases, which were divided into training and testing datasets. For the training dataset, we included only control subjects with age at recruitment ≥55 years and no family history of diabetes mellitus, yielding a final training dataset sample size of 6,305 T2D cases and 73,922 controls. The remaining 236,236 individuals were used as a test dataset, and were not filtered by age or family history.
PRS models were calculated from the above-mentioned base and training datasets using the PRsice software 77 with default settings and clumping parameters (--clump-r2 0.6 --clump-p 0.01). We included 11 covariates in the analysis: the seven principal components provided by UK Biobank investigators as well as BMI, age at recruitment, batch information and sex.
We generated PRS models based on the following common genetic variants: (1) the entire genome-wide set shared by the training and testing dataset (total of 5,352,737 variants; 1,152 qualifying variants in the model), (2) variants overlapping hub pcHi-C baits and enhancers (total variants = 86,158; 179 qualifying variants in the model), (3) variants overlapping islet open chromatin regions, excluding islet hub baits and enhancers and those in LD (r 2 > 0.1) with islet hub index variants (total variants = 269,342; 160 qualifying variants in the model), (4) the remaining genome, excluding variants overlapping islet hub regions or other islet open chromatin regions or those in LD with islet hub index variants (total variants = 4,913,005; 355 qualifying variants in the model).
To enable comparisons of PRS effects in stratified subgroups, we created regions with similar genomic space and distribution as hubs (pseudo-enhancer hubs). Pseudo-enhancer hubs were generated essentially as for LD Score regression analysis, except that they resembled hubs used for PRS, in that they contained all enhancers and baits of hubs. We created 100 sets of ~1,000 pseudo-enhancer hubs by shuffling hub pcHi-C baits and their assigned enhancer fragments across randomly selected size-matched TADs, excluding those in TADs with real hubs or if they crossed TAD boundaries. We then built PRS models using variants overlapping these pseudo-baits and pseudo-enhancers (average of 265 qualifying variants per pseudo-hub PRS model).
To assess PRS, we first stratified the entire UK Biobank test dataset (n = 236,236) in 40 bins, each one containing 2.5% of individuals ranked by PRS score. To enable assessment of PRS for T2D stratified by BMI and age of diagnosis, all measures of T2D frequency were performed exclusively with the 6,127 T2D cases with known age of diagnosis, and diagnosed after 20 years of age, and all 226,777 controls, which were censored at enrollment to UK Biobank. We calculated either the T2D frequency ratios in top versus bottom bin, or the odds ratio for T2D in individuals with highest PRS scores (top 2.5% bin) versus remaining individuals in the same age and BMI categories, using a logistic regression model adjusted for the first seven principal components of ancestry, sex, age, BMI and batch information. We expressed values as Z-scores relative to the distribution of 100 sets of pseudo-hub PRS to enable comparisons of hub scores in the different stratified subgroups.
Data visualization.
Data from this study can be visualized in the following browsers: islet regulome browser (http://isletregulome.org/isletregulome) 17 , CHiCP browser (https://www.chicp.org) 16 and WashU Epigenome browser using this session link: http://epigenomegateway.wustl.edu/browser/?genome=hg19&session =62hGf7nfcS&statusId=140947077 Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
Raw sequence reads from pcHi-C, RNA-seq, ChIP-seq, ATAC-seq and 4C-seq are available from EGA (https://www.ebi.ac.uk/ega), under accession number EGAS00001002917. Processed data files for islet pcHi-C interactions, islet regulome annotations, enhancer-promoter assignments, hub coordinates and components and 3D model videos are provided as supplementary data. The robust set of ATAC-seq peaks, consistent set of Mediator, cohesin, H3K27ac and H3K4me3 peaks, list of islet super-enhancers defined using ROSE algorithm, islet regulome, ChromHMM segmentation model, list of islet TAD-like domains, PATs and the list of high-confidence pcHi-C interactions are provided as Supplementary Datasets and are also deposited at https://www.crg.eu/en/programmes-groups/ ferrer-lab#datasets.
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